Please try another search
4basebio PLC engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company offers AVV and Lentivirus manufacturing services for use in gene therapies and vaccines. It also offers access to its targeted non-viral delivery platform, Hermes. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was founded in 2008 and is based in Cambridge, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Timothy Paul McCarthy | 64 | - | Independent Non-Executive Chairman |
David Roth | - | - | CFO, Company Secretary & Executive Director |
Heikki Lanckriet | - | - | CEO, Chief Scientific Officer & Executive Director |
Hansjoerg Plaggemars | 54 | 2024 | Director |
Michael Jason Wasserman | 50 | 2024 | Director |
Alexander Christian Ansgar Link | 53 | 2024 | Director |
Alan Malus | - | 2024 | Independent Non-executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review